Nippon India Pharma Fund - IDCW Payout Option
Nippon India Mutual Fund
₹117.31 (+0.35%)
NAV as of 9 Oct 2026
Minimum Investment: ₹5,000
Return
6.48% Returns for 1Y
Expense ratio & Others
- Net expense ratio
- 1.81%
- Exit load
- 0%
- Lock-in
- No
- Minimum investment
- ₹5,000
- Category
- Sector - Healthcare
Expense ratio is inclusive of GST. Returns may be taxed based on the fund type and your holding period — please read the scheme-related documents and consult a tax advisor. Figures are historical and do not guarantee future results.
Fund Returns Estimator
One-time investment
₹1,000
6 months
₹1,099
Invested ₹1,000
▲+9.91%1 year
₹1,065
Invested ₹1,000
▲+6.48%3 years
₹1,153
Invested ₹1,000
▲+15.31%5 years
₹1,125
Invested ₹1,000
▲+12.46%
Based on the fund’s historic trailing returns — a planning illustration, not a guarantee of future results.
Invest One-TimePlan it your way
The figures above are fixed to this fund’s past returns over set periods. Use a calculator to set your own amount, tenure and expected rate of return.
Risk level
Riskometer scale
- Low
- Low to Moderate
- Moderate
- Moderate to High
- High
- Very HighThis fund
Riskometer level assigned by the fund house as per SEBI norms. It can change as the scheme’s portfolio changes.
Fund benchmark
| Primary Index Name | BSE Healthcare PR INR |
|---|---|
| Secondary Index Name | BSE Healthcare PR INR |
| Index Name | BSE Healthcare TR INR |
| Weighting | 100% |
Returns
| 1Y | 3Y | 5Y | 10Y | |
|---|---|---|---|---|
| Fund returns (%) | +6.48% | +15.31% | +12.46% | — |
| Cumulative returns (%) | +6.48% | +53.34% | +79.86% | +305.31% |
Fund Manager
| Manager | Amber Singhania |
|---|---|
| Role | Manager |
| Manager Tenure | 0.56 yrs |
About Fund
| Date of Incorporation | 5 Jun 2004 |
|---|---|
| Fund House | Nippon India Mutual Fund |
| Custodian | Deutsche Bank AG |
| Registrar / Transfer Agent | Nippon Life India Asset Management Ltd |
| Address | 1 Great Winchester Street |
Top Holdings
| Company | Weightage (%) |
|---|---|
| Sun Pharmaceuticals Industries Ltd | 12.37% |
| Divi's Laboratories Ltd | 7.00% |
| Lupin Ltd | 6.43% |
| Cipla Ltd | 6.09% |
| Apollo Hospitals Enterprise Ltd | 5.15% |
| Dr Reddy's Laboratories Ltd | 4.93% |
| Mankind Pharma Ltd | 4.09% |
| Sai Life Sciences Ltd | 3.94% |
| Medplus Health Services Ltd | 3.68% |
| Ajanta Pharma Ltd | 3.47% |
| Vijaya Diagnostic Centre Ltd | 3.36% |
| GlaxoSmithKline Pharmaceuticals Ltd | 3.31% |
| Max Healthcare Institute Ltd Ordinary Shares | 3.15% |
| Gland Pharma Ltd | 3.05% |
Investment Strategy
The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.
"The fund seeks to invest in pharma sector with focus on important segments of the sector viz Domestic Business, International & CRAMS and include deep value as well as high growth pharma businesses. The fund invests across market capitalization within the sector. It may suit investment horizon of around 2-3 years."
Mutual fund investments are subject to market risks. Read all scheme-related documents carefully. The data shown is for information only and does not constitute investment advice.